Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03722823 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT03722823 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 37 participants.
The verdict
NCT03722823, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The investigators are doing this study to find out if tucatinib is safe for patients with liver problems. This study will look at participants with mild, moderate, and severe liver problems. For each participant with liver problems who takes part, a matching healthy participant who is of similar age, similar body mass index (BMI), and of the same sex will also take part. The study will look at how the drug affects healthy participants compared to participants with liver problems.
Interventions
- DRUG Tucatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2019-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03722823
The ClinicalTrials.gov registry entry for NCT03722823 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tucatinib is the first listed.
NCT03722823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03722823 about?
NCT03722823 is a clinical study titled "A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects". The investigators are doing this study to find out if tucatinib is safe for patients with liver problems. This study will look at participants with mild, moderate, and severe liver problems. For each participant with liver problems who takes part, a matching healthy participant who is of similar age...
What is the current status of trial NCT03722823?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2018-10-10. Estimated completion is 2019-05-07.
What interventions are being tested in trial NCT03722823?
The interventions under investigation include: Tucatinib (DRUG).
Who is sponsoring clinical trial NCT03722823?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.